Insider Transactions in Q2 2024 at Dyne Therapeutics, Inc. (DYN)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,163
-6.39%
|
$355,705
$35.33 P/Share
|
|
Jun 24
2024
|
Susanna Gatti High Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,163
+6.01%
|
$50,815
$5.54 P/Share
|
|
Jun 21
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
29,787
-16.68%
|
$1,042,545
$35.01 P/Share
|
|
Jun 21
2024
|
Susanna Gatti High Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,787
+14.3%
|
$148,935
$5.54 P/Share
|
|
Jun 12
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
40,000
-11.19%
|
$1,320,000
$33.43 P/Share
|
|
Jun 12
2024
|
Susanna Gatti High Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+17.48%
|
$200,000
$5.54 P/Share
|
|
Jun 11
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,636
-0.89%
|
$81,716
$31.27 P/Share
|
|
Jun 11
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,136
-1.43%
|
$66,216
$31.34 P/Share
|
|
Jun 11
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,823
-1.33%
|
$56,513
$31.34 P/Share
|
|
Jun 11
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,270
-1.73%
|
$163,370
$31.23 P/Share
|
|
Jun 11
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,331
-1.16%
|
$41,261
$31.34 P/Share
|
|
Jun 10
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
80,000
-34.18%
|
$2,400,000
$30.24 P/Share
|
|
Jun 10
2024
|
Susanna Gatti High Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+25.47%
|
$400,000
$5.54 P/Share
|
|
Jun 10
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,590
-1.36%
|
$47,700
$30.23 P/Share
|
|
May 20
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,426
-5.91%
|
$1,004,058
$33.36 P/Share
|
|
May 20
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,426
+14.45%
|
$30,426
$1.03 P/Share
|
|
May 16
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,588
-1.09%
|
$72,464
$28.4 P/Share
|
|
May 16
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,738
-0.88%
|
$76,664
$28.4 P/Share
|
|
May 16
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,381
-0.79%
|
$66,668
$28.4 P/Share
|
|
May 16
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,705
-0.89%
|
$75,740
$28.4 P/Share
|
|
May 16
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,774
-1.0%
|
$77,672
$28.4 P/Share
|